Efficacy of a Bioresorbable Matrix in Healing Complex Chronic Wounds: An Open-Label Prospective Pilot Study

被引:0
|
作者
Manning, Sarah W. [1 ]
Humphrey, David A. [1 ]
Shillinglaw, William R. [1 ]
Crawford, Eric [2 ]
Pranami, Gaurav [2 ]
Agarwal, Ankit [2 ]
Schurr, Michael J. [1 ]
机构
[1] Univ North Carolina Hlth Sci, Mt Area Hlth Educ Ctr, Dept Surg, Asheville, NC USA
[2] Imbed Biosci Inc, Madison, WI 53719 USA
基金
美国国家卫生研究院;
关键词
bioresorbable; antimicrobial; silver; matrix; chronic; wound; infection; SILVER DRESSINGS; CYTOTOXICITY; MANAGEMENT; SYMPTOMS; TISSUE; CELL;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective. The goal of this prospective clinical study was to assess the effectiveness of a novel bioresorbable polymeric matrix impregnated with ionic and metallic silver as a primary wound contact dressing in healing stagnant or deteriorating chronic wounds. Materials and Methods. Thirty-two patients with a total of 35 chronic wounds undergoing treatment at the Wound Healing and Hyperbaric Center at Mission Hospital were recruited under a protocol approved by the institutional review board. The wounds included venous stasis ulcers, diabetic foot ulcers, postoperative surgical wounds, burn wounds, and chronic, nonpressure lower extremity ulcers. At baseline, all wounds were nonhealing (ie, stagnant or deteriorating) for a median of 39 weeks (range, 3-137 weeks) and suspected of persistent microbial colonization that had not responded to traditional antimicrobial products and/or antibiotics. The aforementioned matrix was applied to wounds once every 3 days and covered with a secondary dressing. Previously prescribed protocols of care, such as debridement or compression wraps, were continued, but prior antimicrobial dressings or antibiotics were replaced with the matrix. Wound assessments at 3 weeks and 12 weeks post intervention are reported. Results. Three patients were excluded due to patients lost to follow-up after initial application. At 3 weeks, 72% of wounds (22/32) had significantly improved healing with an average wound area reduction of 66%. By 12 weeks, 91% of wounds (29/32) either healed completely (ie, fully reepithelialized) or improved significantly with an average wound area reduction of 73%. The matrix was well tolerated; no patient reported discomfort with the application of the matrix. Conclusions. The micrometer-thick bioresorbable matrix presents a new form factor to wound management, conforming intimately to the underlying wound bed to exert localized and sustained antimicrobial action of noncytotoxic levels of silver. The application of the matrix on the wound surface in protocols of care was safe and well tolerated, and it facilitated improvements in healing of a majority of the stagnant or deteriorating complex chronic wounds.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [31] Ziprasidone in adolescents with autism: An open-label pilot study
    Malone, Richard P.
    Delaney, Mary Anne
    Hyman, Susan B.
    Cater, Jacqueline R.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 779 - 790
  • [32] Cladribine in myasthenia gravis: a pilot open-label study
    Rejdak, K.
    Szklener, S.
    Korchut, A.
    Baranowski, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 (03) : 586 - 589
  • [33] Escitalopram for perimenopausal depression: An open-label pilot study
    Freeman, Marlene P.
    Hill, Rebecca
    Brumbach, Barbara H.
    JOURNAL OF WOMENS HEALTH, 2006, 15 (07) : 857 - 861
  • [34] Acamprosate in bipolar disorder: an open-label pilot study
    Dittmann, S.
    Grunze, H. C.
    Kupka, R.
    Nolen, W.
    Bauer, M.
    Schaerer, L.
    Walden, J.
    Post, R.
    Frye, M.
    BIPOLAR DISORDERS, 2009, 11 : 35 - 35
  • [35] Memantine for Alcohol Dependence: An Open-label Pilot Study
    Arias, Albert J.
    Feinn, Richard
    Covault, Jonathan
    Kranzler, Henry R.
    ADDICTIVE DISORDERS & THEIR TREATMENT, 2007, 6 (02): : 77 - 83
  • [36] Efficacy of tacrolimus in primary kidney transplant patients: Multicenter, open-label prospective study
    Park, K
    Ahn, C
    Bang, BK
    Kang, CM
    Kim, SI
    Kim, SJ
    Kim, YS
    Kim, YS
    Koh, YB
    Kwak, JY
    Kwon, OJ
    Moon, IS
    Moon, JI
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 1705 - 1708
  • [37] An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma
    Bousson, Valerie
    Leturcq, Tifenn
    Ea, Hang-Korng
    Hauger, Olivier
    Mehsen-Cetre, Nadia
    Hamze, Bassam
    Parlier-Cuau, Caroline
    Laredo, Jean-Denis
    Schaeverbeke, Thierry
    Orcel, Philippe
    EUROPEAN RADIOLOGY, 2018, 28 (02) : 478 - 486
  • [38] An open-label pilot study of levetiracetam for essential tremor
    Ondo, WG
    Jimenez, JE
    Vuong, KD
    Jankovic, J
    CLINICAL NEUROPHARMACOLOGY, 2004, 27 (06) : 274 - 277
  • [39] An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma
    Valérie Bousson
    Tifenn Leturcq
    Hang-Korng Ea
    Olivier Hauger
    Nadia Mehsen-Cetre
    Bassam Hamzé
    Caroline Parlier-Cuau
    Jean-Denis Laredo
    Thierry Schaeverbeke
    Philippe Orcel
    European Radiology, 2018, 28 : 478 - 486
  • [40] Pilot open-label study of nefazodone in panic disorder
    Bystritsky, A
    Rosen, R
    Suri, R
    Vapnik, T
    DEPRESSION AND ANXIETY, 1999, 10 (03) : 137 - 139